CA2847888A1 - Methods and compositions for controlling assembly of viral proteins - Google Patents

Methods and compositions for controlling assembly of viral proteins Download PDF

Info

Publication number
CA2847888A1
CA2847888A1 CA2847888A CA2847888A CA2847888A1 CA 2847888 A1 CA2847888 A1 CA 2847888A1 CA 2847888 A CA2847888 A CA 2847888A CA 2847888 A CA2847888 A CA 2847888A CA 2847888 A1 CA2847888 A1 CA 2847888A1
Authority
CA
Canada
Prior art keywords
seq
core protein
modified
protein
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2847888A
Other languages
English (en)
French (fr)
Inventor
Miguel De Los Rios
Stephanie De Los Rios
Jacek Ostrowski
Kenneth J. Oh
Ilan ZIPKIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomed Realty LP
Original Assignee
Biomed Realty LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Realty LP filed Critical Biomed Realty LP
Publication of CA2847888A1 publication Critical patent/CA2847888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2847888A 2011-09-09 2012-09-10 Methods and compositions for controlling assembly of viral proteins Abandoned CA2847888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532986P 2011-09-09 2011-09-09
US61/532,986 2011-09-09
PCT/US2012/054534 WO2013036973A2 (en) 2011-09-09 2012-09-10 Methods and compositions for controlling assembly of viral proteins

Publications (1)

Publication Number Publication Date
CA2847888A1 true CA2847888A1 (en) 2013-03-14

Family

ID=47832822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2847888A Abandoned CA2847888A1 (en) 2011-09-09 2012-09-10 Methods and compositions for controlling assembly of viral proteins

Country Status (6)

Country Link
US (2) US8865188B2 (enExample)
EP (1) EP2747774A4 (enExample)
JP (1) JP2014527072A (enExample)
AU (1) AU2012305714A1 (enExample)
CA (1) CA2847888A1 (enExample)
WO (1) WO2013036973A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
EP2747774A4 (en) * 2011-09-09 2015-02-11 Biomed Realty L P METHOD AND COMPOSITIONS FOR CONTROLLING VIRUS PROTECTION
CA2936092A1 (en) * 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN106279379B (zh) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 一种免疫原HM4-M2e及其制备方法与应用
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物
CN107488217A (zh) * 2017-09-13 2017-12-19 华兰生物疫苗有限公司 一种多肽、免疫原性偶联物和流感疫苗
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2020075836A1 (ja) * 2018-10-12 2020-04-16 国立研究開発法人理化学研究所 Ｂ型肝炎ウイルス複製阻害剤及びそれを含むｂ型肝炎治療用医薬組成物
US11261216B2 (en) * 2018-12-28 2022-03-01 The Board Of Trustees Of The Leland Stanford Junior University Engineered hepatitis B core polypeptide
CN110125434B (zh) * 2019-05-14 2022-07-29 东南大学 一种光热金纳米材料的制备方法
EP4103588A1 (en) * 2020-02-13 2022-12-21 The Trustees of Indiana University Hepadnavirus capsid protein heterodimers and virus-like particles
GB202210507D0 (en) * 2022-07-18 2022-08-31 Univ Dundee Virus-like particles, heterodimeric capsid proteins and methods of production thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
NZ228948A (en) 1988-05-13 1991-06-25 Phillips Petroleum Co Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
WO1992003537A1 (en) 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
JPH10505320A (ja) 1994-05-31 1998-05-26 イネックス ファーマシューティカルズ コーポレイション 治療剤のビロゾーム媒介細胞内輸送
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
ATE382694T1 (de) 1995-11-28 2008-01-15 Genvec Inc Vektoren und methoden zum gentransfer in zellen
US6284494B1 (en) 1995-12-12 2001-09-04 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes
WO1997037680A1 (en) 1996-04-05 1997-10-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
AU4353897A (en) 1996-09-18 1998-04-14 Board Of Regents, The University Of Texas System Viral defective interfering particles and uses thereof
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
US6180389B1 (en) 1997-01-03 2001-01-30 The Research And Development Institute, Inc. Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
TR200002338T2 (tr) 1998-02-12 2002-06-21 Immune Complex Corporation Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
WO2000008654A1 (en) 1998-08-05 2000-02-17 Sony Corporation Composition for electrolyte, electrolyte and process for producing the same, and cell containing the same
AU5556799A (en) 1998-08-12 2000-03-06 University Of Virginia Patent Foundation Assay for assembly of herpes simplex virus capsid
EP1845163A3 (en) 1998-11-05 2007-10-31 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP2360174B1 (en) 1998-12-04 2014-04-09 Biogen Idec MA Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
JP2003504014A (ja) 1999-06-30 2003-02-04 エボテック オーアーイー アクチェンゲゼルシャフト ウイルス状粒子、それらの調製及び好ましくは薬学的スクリーニング及び機能的ゲノムにおけるそれらの使用
US20020064520A1 (en) 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
IL153831A0 (en) 2000-07-19 2003-07-31 Univ California Methods for therapy of neurodegenerative disease of the brain
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
SI1407044T2 (en) 2000-12-01 2018-03-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
AU2002230647A1 (en) 2000-12-01 2002-06-11 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Cell-free assembly of lentiviral capsids
EP1219705B1 (en) 2000-12-29 2007-11-28 Evotec AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
EP1409748B1 (en) 2001-06-22 2011-10-26 The Trustees of The University of Pennsylvania Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US20050089526A1 (en) 2001-09-06 2005-04-28 Moore John P. Human immunodeficiency virus envelope clycoprotein mutants and uses thereof
US7148343B2 (en) 2001-10-12 2006-12-12 Gentra Systems, Inc. Compositions and methods for using a solid support to purify RNA
CA2852277C (en) 2001-11-21 2018-02-20 Guangping Gao Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2469785C (en) 2001-12-17 2014-04-22 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1447079A1 (de) 2003-02-15 2004-08-18 Fraunhofer-Gesellschaft für angewandte Forschung e.V. Vesikel mit chimären Rezeptoren zur Induktion einer gerichteten T-Zellantwort in vivo
US7179484B2 (en) 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
JP2004175665A (ja) 2002-11-22 2004-06-24 Japan Science & Technology Agency タンパク質中空ナノ粒子およびそれを用いた薬剤
HUE040046T2 (hu) 2002-12-09 2019-02-28 Abraxis Bioscience Llc Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1685376A4 (en) 2003-10-15 2010-03-03 Univ Texas VIRUS FIBERS
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
EP1785433A4 (en) 2004-07-01 2008-10-01 Tokyo Inst Tech VIRAL PARTICLE-LIKE CONSTRUCTION AND PROCESS FOR FORMING THE SAME IN PHYSIOLOGICAL CONDITIONS
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
CA2579519A1 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
CN101068567A (zh) 2004-09-17 2007-11-07 科·汉森有限公司 嵌合噬菌体衍生的颗粒，它们的制造方法和用途
CN2763975Y (zh) 2004-12-11 2006-03-08 鸿富锦精密工业（深圳）有限公司 热管式散热装置
EP2270136A1 (en) 2004-12-17 2011-01-05 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
WO2006088229A1 (ja) 2005-02-16 2006-08-24 The Circle For The Promotion Of Science And Engineering 改変されたウイルスカプシドタンパク質及びその使用
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
WO2008037504A1 (en) 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
WO2008048288A2 (en) 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
WO2007126764A2 (en) 2006-03-27 2007-11-08 The Regents Of The University Of California Chemically modified viral capsids as targeted delivery vectors for diagnostic and therapeutic agents
US8067011B2 (en) 2006-04-07 2011-11-29 Chimeros, Inc. Compositions and methods for treating B-cell malignancies
DK2012822T3 (da) 2006-04-28 2010-05-25 Univ Pennsylvania Modificeret adenovirushexonprotein og anvendelser deraf
WO2008027084A2 (en) 2006-04-28 2008-03-06 The Trustees Of The University Of Pennsylvania Modified aav vectors having reduced capsid immunogenicity and use thereof
EP2024076A1 (en) 2006-05-22 2009-02-18 Nizo Food Research B.V. Protein encapsulated partocles
AU2007286203B2 (en) 2006-08-08 2013-05-02 Board Of Regents, The University Of Texas System Multistage delivery of active agents
US9803189B2 (en) 2006-08-23 2017-10-31 Stc.Unm Virus-like platform for rapid vaccine discovery
WO2008051101A1 (en) 2006-10-25 2008-05-02 Universidade De Coimbra Oral submicron particle delivery system for proteins and process for its production
US20090226525A1 (en) * 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
CA2597878A1 (en) * 2007-09-13 2009-03-13 Ankegens Laboratories Capsid protein and use therefore
WO2010042749A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042743A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric multiplexes, compositions, and methods for using same
WO2010042751A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
EP2747774A4 (en) 2011-09-09 2015-02-11 Biomed Realty L P METHOD AND COMPOSITIONS FOR CONTROLLING VIRUS PROTECTION

Also Published As

Publication number Publication date
EP2747774A4 (en) 2015-02-11
WO2013036973A3 (en) 2013-07-11
AU2012305714A1 (en) 2014-03-27
WO2013036973A2 (en) 2013-03-14
US20150252081A1 (en) 2015-09-10
EP2747774A2 (en) 2014-07-02
JP2014527072A (ja) 2014-10-09
US20130156818A1 (en) 2013-06-20
US8865188B2 (en) 2014-10-21

Similar Documents

Publication Publication Date Title
US8865188B2 (en) Methods and compositions for controlling assembly of viral proteins
US6267964B1 (en) Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
JP5902679B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
US11472876B2 (en) Conditionally active polypeptides
CA2064689C (en) Stabilized protein or peptide conjugates
US20140010885A1 (en) Self-assembling nanoparticle drug delivery system
JP7680745B2 (ja) １価ｃｃａｐ生成物の製造方法
AU2019218786B2 (en) Cell-permeable stapled peptide modules for cellular delivery
JP7385680B2 (ja) 変異型ｒｓｖ ｆタンパク質及びその利用
CN106906230B (zh) 重组药物载体蛋白基因及其制备方法与应用
CN114616241B (zh) 基于铁蛋白重链亚基的药物载体
JP2001520206A (ja) 上皮細胞標的化結合体としてのｊ鎖およびアナログ
JP2019520392A (ja) ヒト酵素媒介性シスチン枯渇
US20110104263A1 (en) Claudin-4 binding peptides, compositions and methods of use
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
JP2001511122A (ja) 新規な上皮組織標的化薬剤
CN112225820B (zh) 肿瘤特异靶向性基质的重组人血清白蛋白-胶原结合域融合蛋白和应用
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
US9238010B2 (en) Vesicles and nanostructures from recombinant proteins
US7078485B2 (en) N-terminal modified recombinant human endostatin and its production
JPH10509038A (ja) 免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製
JPH08507212A (ja) 突然変異型タンパク質並びにそれを製造及び用いるための方法及び物質
CN117327191A (zh) 靶向cd20的笼状蛋白及其应用
CN116897162A (zh) 铁蛋白重链亚基突变体及其应用
HK40065797A (zh) 1价ccap生成物的制造方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180911